Report Overview

The EU Colorectal Cancer Drugs market size stood at USD 3.5 billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period

Colorectal cancer is a cancer that starts in the colon or rectum. Colorectal cancer often begins as a growth called a polyp, which may form on the inner wall of the colon or rectum. Some polyps become cancer over time. Finding and removing polyps can prevent colorectal cancer. Most colorectal cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Some of the commonly seen symptoms of colorectal cancer are blood in the weight loss, fatigue, stool, and irregular bowel movements. An epidemiologic study from the European Union (EU) concluded that in 2018, colorectal cancer would account for the second-highest number of cancer deaths, at 98,000 deaths in men and 79,400 in women. However, while the total number of colorectal deaths in the EU has risen since 2012 because of the aging population, since 2012 the age-standardized death rate has fallen by 6.7% (to 15.8 per 100,000 in men and 7.5% (to 9.2 per 100,000) in women.Behavioral risk factors (such as diet, alcohol intake, and physical inactivity) account for a large proportion of cases



Market Growth Drivers

Factors that are driving the European colorectal cancer drug market growth include the advent of efficacious genetic tests, a growing burden of colorectal cancer. Further, Screening Tests for colorectal cancers are anticipated to drive the EU market